GT Biopharma (NASDAQ:GTBP) Stock Scheduled to Reverse Split on Tuesday, September 8th

GT Biopharma, Inc. (NASDAQ:GTBP)’s stock is set to reverse split before the market opens on Tuesday, September 8th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, September 7th.

GT Biopharma Stock Performance

GTBP stock traded down $0.01 during trading on Friday, hitting $0.24. The company had a trading volume of 1,158,788 shares, compared to its average volume of 448,466. GT Biopharma has a 12 month low of $0.22 and a 12 month high of $1.37. The firm has a 50-day moving average price of $0.34 and a 200-day moving average price of $0.39.

GT Biopharma (NASDAQ:GTBP) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.04). Analysts forecast that GT Biopharma will post -0.43 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of GT Biopharma in a research note on Wednesday, July 8th. Wall Street Zen upgraded shares of GT Biopharma to a “hold” rating in a report on Saturday, June 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On GT Biopharma

A hedge fund recently bought a new stake in GT Biopharma stock. 49 Wealth Management LLC purchased a new stake in GT Biopharma, Inc. (NASDAQ:GTBP) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 64,000 shares of the company’s stock, valued at approximately $31,000. 49 Wealth Management LLC owned about 0.14% of GT Biopharma at the end of the most recent quarter. Institutional investors and hedge funds own 8.15% of the company’s stock.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).